Sclerosing cholangitis.
PURPOSE OF REVIEW: Primary sclerosing cholangitis is a chronic cholestatic liver disease characterized by strictures of the biliary tree. It is immune mediated, although the precise cause remains unknown. Recent reports have shown a higher prevalence and burden of disease than was previously suspec...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2005
|
| _version_ | 1797052195529555968 |
|---|---|
| author | MacFaul, G Chapman, R |
| author_facet | MacFaul, G Chapman, R |
| author_sort | MacFaul, G |
| collection | OXFORD |
| description | PURPOSE OF REVIEW: Primary sclerosing cholangitis is a chronic cholestatic liver disease characterized by strictures of the biliary tree. It is immune mediated, although the precise cause remains unknown. Recent reports have shown a higher prevalence and burden of disease than was previously suspected. RECENT FINDINGS: The research into the etiopathogenesis, epidemiology, diagnosis of cholangiocarcinoma, medical and surgical therapy, and timing and outcome of liver transplantation is discussed. SUMMARY: Genetic heterogeneity among patients with primary sclerosing cholangitis is supported, and further gene polymorphisms associated with protection against primary sclerosing cholangitis have been elucidated. Bile duct injury seems to be a multistep process. Magnetic resonance cholangiopancreatography is a cost-effective and accurate way of diagnosing primary sclerosing cholangitis in comparison with endoscopic retrograde cholangiopancreatography. Ursodeoxycholic acid may have a role as a colorectal and hepatobiliary cancer chemopreventive agent. Liver transplantation remains the only treatment in end-stage disease. The 5-year and 10-year patient and graft survival rates are comparable with those in patients without primary sclerosing cholangitis, but there is a higher rate of retransplantation for primary sclerosing cholangitis in most centers. Hepatobiliary malignancy is found in a minority of patients at transplantation, although 5-year survival rates for these patients are still promising. |
| first_indexed | 2024-03-06T18:29:03Z |
| format | Journal article |
| id | oxford-uuid:08fdc993-317a-49a5-8de8-d4f98d46aec7 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:29:03Z |
| publishDate | 2005 |
| record_format | dspace |
| spelling | oxford-uuid:08fdc993-317a-49a5-8de8-d4f98d46aec72022-03-26T09:15:55ZSclerosing cholangitis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:08fdc993-317a-49a5-8de8-d4f98d46aec7EnglishSymplectic Elements at Oxford2005MacFaul, GChapman, R PURPOSE OF REVIEW: Primary sclerosing cholangitis is a chronic cholestatic liver disease characterized by strictures of the biliary tree. It is immune mediated, although the precise cause remains unknown. Recent reports have shown a higher prevalence and burden of disease than was previously suspected. RECENT FINDINGS: The research into the etiopathogenesis, epidemiology, diagnosis of cholangiocarcinoma, medical and surgical therapy, and timing and outcome of liver transplantation is discussed. SUMMARY: Genetic heterogeneity among patients with primary sclerosing cholangitis is supported, and further gene polymorphisms associated with protection against primary sclerosing cholangitis have been elucidated. Bile duct injury seems to be a multistep process. Magnetic resonance cholangiopancreatography is a cost-effective and accurate way of diagnosing primary sclerosing cholangitis in comparison with endoscopic retrograde cholangiopancreatography. Ursodeoxycholic acid may have a role as a colorectal and hepatobiliary cancer chemopreventive agent. Liver transplantation remains the only treatment in end-stage disease. The 5-year and 10-year patient and graft survival rates are comparable with those in patients without primary sclerosing cholangitis, but there is a higher rate of retransplantation for primary sclerosing cholangitis in most centers. Hepatobiliary malignancy is found in a minority of patients at transplantation, although 5-year survival rates for these patients are still promising. |
| spellingShingle | MacFaul, G Chapman, R Sclerosing cholangitis. |
| title | Sclerosing cholangitis. |
| title_full | Sclerosing cholangitis. |
| title_fullStr | Sclerosing cholangitis. |
| title_full_unstemmed | Sclerosing cholangitis. |
| title_short | Sclerosing cholangitis. |
| title_sort | sclerosing cholangitis |
| work_keys_str_mv | AT macfaulg sclerosingcholangitis AT chapmanr sclerosingcholangitis |